Vlad Ratziu
#116,097
Most Influential Person Now
Researcher
Vlad Ratziu's AcademicInfluence.com Rankings
Vlad Ratziubiology Degrees
Biology
#6731
World Rank
#9511
Historical Rank
Cell Biology
#229
World Rank
#237
Historical Rank
Neuroscience
#818
World Rank
#852
Historical Rank
Biochemistry
#883
World Rank
#991
Historical Rank
Download Badge
Biology
Vlad Ratziu's Degrees
- PhD Biomedical Sciences Université Paris Cité
- Masters Biochemistry Université Paris Cité
- Bachelors Biology Université Paris Cité
Similar Degrees You Can Earn
Why Is Vlad Ratziu Influential?
(Suggest an Edit or Addition)Vlad Ratziu's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. (2016) (1859)
- Viral hepatitis B (2003) (1770)
- Sampling variability of liver biopsy in nonalcoholic fatty liver disease. (2005) (1766)
- Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study (2001) (1467)
- A new definition for metabolic associated fatty liver disease: an international expert consensus statement. (2020) (1099)
- A position statement on NAFLD/NASH based on the EASL 2009 special conference. (2010) (990)
- Liver fibrosis in overweight patients. (2000) (951)
- Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. (2018) (881)
- Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. (2001) (774)
- Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. (2016) (741)
- Endpoints and clinical trial design for nonalcoholic steatohepatitis (2011) (635)
- Effect of treatment with peginterferon or interferon alfa‐2b and ribavirin on steatosis in patients infected with hepatitis C (2003) (622)
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial (2019) (620)
- Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. (2008) (569)
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. (2020) (504)
- A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis (2018) (481)
- Survival, liver failure, and hepatocellular carcinoma in obesity‐related cryptogenic cirrhosis (2002) (476)
- Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease (2006) (474)
- TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease (2014) (468)
- A comparison of fibrosis progression in chronic liver diseases. (2003) (447)
- Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis (2016) (426)
- A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. (2013) (410)
- NASH limits anti-tumour surveillance in immunotherapy-treated HCC (2021) (402)
- Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. (2008) (401)
- Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C (2004) (379)
- Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. (2003) (352)
- Long‐term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial (2010) (349)
- The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis (2005) (342)
- Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. (2004) (342)
- Hepatoprotective effects of the dual peroxisome proliferator‐activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (2013) (341)
- Expression of connective tissue growth factor in experimental rat and human liver fibrosis (1999) (336)
- From NAFLD in clinical practice to answers from guidelines. (2013) (332)
- Meta-analyses of FibroTest diagnostic value in chronic liver disease (2007) (320)
- The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. (2012) (314)
- Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease (2014) (308)
- NAFLD and liver transplantation: Current burden and expected challenges. (2016) (292)
- Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease (2006) (286)
- A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. (2011) (285)
- Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. (2011) (273)
- Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. (1999) (267)
- Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (2018) (254)
- A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. (2006) (252)
- Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. (2007) (251)
- Zf9, a Kruppel-like transcription factor up-regulated in vivo during early hepatic fibrosis. (1998) (250)
- Transcriptional activation of transforming growth factor beta1 and its receptors by the Kruppel-like factor Zf9/core promoter-binding protein and Sp1. Potential mechanisms for autocrine fibrogenesis in response to injury. (1998) (249)
- Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis (2017) (248)
- Current efforts and trends in the treatment of NASH. (2015) (241)
- Natural history and predictors of disease severity in chronic hepatitis C. (2006) (241)
- Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial (2002) (231)
- Fatigue in patients with chronic hepatitis C (2002) (228)
- Ela fi branor , an Agonist of the Peroxisome Proliferator L Activated Receptor L a and L d , Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening (220)
- Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients (2003) (214)
- Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. (2018) (208)
- EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease (2016) (205)
- Appropriateness of liver biopsy. (2000) (203)
- Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically-characterised cohort. (2020) (202)
- Fibrosis in patients with chronic hepatitis C: detection and significance. (2000) (187)
- Transcriptional activation of endoglin and transforming growth factor-beta signaling components by cooperative interaction between Sp1 and KLF6: their potential role in the response to vascular injury. (2002) (184)
- Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest) (2010) (175)
- Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. (1999) (174)
- Concordance of sustained virological response 4, 12, and 24 weeks post‐treatment with sofosbuvir‐containing regimens for hepatitis C virus (2015) (172)
- Liver fibrosis evaluation using real-time shear wave elastography: applicability and diagnostic performance using methods without a gold standard. (2013) (171)
- Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design. (2016) (167)
- Advancing the global public health agenda for NAFLD: a consensus statement (2021) (167)
- Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. (2005) (166)
- Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study (2020) (165)
- Fibrogenic impact of high serum glucose in chronic hepatitis C. (2003) (162)
- Letter regarding article by Ruttmann et al, "gamma-Glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults". (2006) (161)
- Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). (2015) (157)
- A phase 2, randomized, double‐blind, placebo‐controlled study of GS‐9450 in subjects with nonalcoholic steatohepatitis (2012) (156)
- The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials (2019) (150)
- Serum adipokine levels predictive of liver injury in non‐alcoholic fatty liver disease (2009) (147)
- Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. (2013) (143)
- A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. (2021) (137)
- Longitudinal Assessment of Histology Surrogate Markers (FibroTest–ActiTest) During Lamivudine Therapy in Patients with Chronic Hepatitis B Infection (2005) (135)
- Natural history of HCV infection. (2000) (129)
- Performance of Biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in Patients with Severe Obesity: Meta Analysis of Individual Patient Data (2012) (127)
- Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. (2012) (125)
- Hepatitis C in 6,865 Patients 65 yr or Older: A Severe and Neglected Curable Disease? (2006) (114)
- Truth Survival in Clinical Research: An Evidence-Based Requiem? (2002) (113)
- Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis (2020) (112)
- Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. (2014) (111)
- The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C (2004) (110)
- Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®). (2014) (107)
- Liver stiffness is an unreliable marker of liver fibrosis in patients with cardiac insufficiency (2008) (106)
- Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. (2013) (105)
- A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. (2020) (104)
- Biochemical Markers of Fibrosis in Patients with Chronic Hepatitis C: A Comparison with Prothrombin Time, Platelet Count, and Age–Platelet Index (2004) (102)
- Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis. (2012) (99)
- A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. (2020) (98)
- Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity (2019) (97)
- Concordance in a World without a Gold Standard: A New Non-Invasive Methodology for Improving Accuracy of Fibrosis Markers (2008) (97)
- Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation (2007) (97)
- Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science (2017) (97)
- Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C (2002) (95)
- Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C. (2002) (95)
- Portal myofibroblasts promote vascular remodeling underlying cirrhosis formation through the release of microparticles (2015) (91)
- Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard. (2012) (88)
- Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease (2016) (86)
- Development and Validation of Hepamet Fibrosis Scoring System-a Simple, Non-invasive Test to Identify Patients With Nonalcoholic Fatty liver Disease With Advanced Fibrosis. (2019) (86)
- Meta‐analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 Update (2001) (85)
- Regenerate: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. (2019) (83)
- Diagnostic and predictive factors of significant liver fibrosis and minimal lesions in patients with persistent unexplained elevated transaminases. A prospective multicenter study. (2006) (82)
- Fatty liver is an independent predictor of early carotid atherosclerosis. (2016) (81)
- Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta‐analysis (2019) (81)
- Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis. (2021) (80)
- Prognostic value of liver fibrosis biomarkers: a meta-analysis. (2011) (79)
- An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load (2008) (78)
- Progression from isolated steatosis to steatohepatitis and fibrosis in nonalcoholic fatty liver disease. (2011) (77)
- Therapeutic trials in nonalcoholic steatohepatitis: Insulin sensitizers and related methodological issues (2010) (75)
- Temporal trends, clinical patterns and outcomes of NAFLD‐related HCC in patients undergoing liver resection over a 20‐year period (2017) (75)
- Histological progression of non‐alcoholic fatty liver disease: a critical reassessment based on liver sampling variability (2007) (74)
- Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease (2019) (73)
- Assessing the outcome of nonalcoholic steatohepatitis? It's time to get serious (2006) (73)
- An overview of nonalcoholic steatohepatitis: past, present and future directions. (2010) (71)
- Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference (2016) (70)
- Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population. (2012) (70)
- Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference (2016) (70)
- Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age (2011) (67)
- Screening for liver disease using non‐invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia (2006) (67)
- Blood oxidative stress markers are unreliable markers of hepatic steatosis (2006) (67)
- Biomarkers of Liver Injury for Hepatitis Clinical Trials: A Meta-Analysis of Longitudinal Studies (2010) (66)
- Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B (2011) (66)
- A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. (2019) (64)
- Screening for liver fibrosis by using a noninvasive biomarker in patients with diabetes. (2008) (64)
- A survey of patterns of practice and perception of NAFLD in a large sample of practicing gastroenterologists in France. (2012) (64)
- FibroMAX™: towards a new universal biomarker of liver disease? (2007) (64)
- 10 RESULTS OF A PROOF OF CONCEPT STUDY (C210) OF TELAPREVIR MONOTHERAPY AND IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 4 HCV PATIENTS (2009) (64)
- Pharmacological agents for NASH (2013) (62)
- Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient – death of a dogma from analysis of therapeutic studies? (2011) (60)
- Facial Cosmetic Filler Injections as Possible Target for Systemic Sarcoidosis in Patients Treated with Interferon for Chronic Hepatitis C: Two Cases (2008) (60)
- TM 6 SF 2 rs 58542926 Influences Hepatic Fibrosis Progression in Patients with Non-Alcoholic Fatty Liver Disease (2014) (59)
- Significant variations in elastometry measurements made within short-term in patients with chronic liver diseases. (2015) (59)
- Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. (2008) (58)
- Non-invasive detection of liver fibrosis: Is superparamagnetic iron oxide particle-enhanced MR imaging a contributive technique? (2003) (57)
- Systematic review of bariatric surgery liver biopsies clarifies the natural history of liver disease in patients with severe obesity (2016) (57)
- A constellation of cardiovascular risk factors is associated with hepatic enzyme elevation in hyperlipidemic patients. (2002) (57)
- Plasma bilirubin and gamma-glutamyltransferase activity are inversely related in dyslipidemic patients with metabolic syndrome: relevance to oxidative stress. (2010) (56)
- The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge? (2021) (56)
- FibroTest-FibroSURE™: towards a universal biomarker of liver fibrosis? (2005) (56)
- A critical review of endpoints for non-cirrhotic NASH therapeutic trials. (2018) (56)
- Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease. (2019) (55)
- Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum (2019) (55)
- The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease. (2006) (55)
- GS-06-Positive Results from REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH (2019) (54)
- Randomized Study of Asunaprevir plus Pegylated Interferon-α and Ribavirin for Previously Untreated Genotype 1 Chronic Hepatitis C (2013) (52)
- Assessment of Liver Fibrosis: Noninvasive Means (2008) (51)
- Fat, diabetes, and liver injury in chronic hepatitis C (2004) (51)
- Diagnostic value of serum protein profiling by SELDI‐TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C (2007) (50)
- Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial (2021) (50)
- Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest–ActiTest) in patients infected by hepatitis B virus (2009) (50)
- Portal lymphocytic infiltrate in alcoholic liver disease. (2002) (49)
- Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease. (2015) (49)
- Effect of interferon therapy on the natural history of hepatitis C virus-related cirrhosis and hepatocellular carcinoma. (1999) (49)
- [Treatment and prevention of hepatitis C]. (2000) (48)
- Disease burden and economic impact of diagnosed non‐alcoholic steatohepatitis in five European countries in 2018: A cost‐of‐illness analysis (2021) (48)
- Biomarkers of liver fibrosis. (2008) (48)
- TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial. (2021) (47)
- Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study (2020) (46)
- Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. (2008) (46)
- [Epidemiology and natural history of nonalcoholic fatty liver disease]. (2012) (45)
- Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update. (2001) (45)
- Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson’s disease (2006) (44)
- Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy? (2005) (44)
- Why do so many NASH trials fail? (2020) (44)
- The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. (2018) (42)
- Diagnostic Modalities for Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) and Associated Fibrosis (2017) (42)
- The European NAFLD registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. (2020) (42)
- Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. (2019) (41)
- Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis. (2014) (40)
- Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study (2019) (39)
- Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®). (2014) (39)
- Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial. (2013) (39)
- Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest) (2004) (38)
- What are the best reference values for a normal serum alanine transaminase activity (ALT)? Impact on the presumed prevalence of drug induced liver injury (DILI). (2011) (38)
- Non-alcoholic fatty liver - perhaps not so benign. (2015) (38)
- Review article: an unexpected virus–host interaction – the hepatitis C virus‐diabetes link (2005) (37)
- Novel Pharmacotherapy Options for NASH (2016) (36)
- ActiTest accuracy for the assessment of histological activity grades in patients with chronic hepatitis C, an overview using Obuchowski measure. (2010) (35)
- Successful rescue therapy with tenofovir in a patient with hepatic decompensation and adefovir resistant HBV mutant (2006) (35)
- Pharmacologic therapy of non-alcoholic steatohepatitis. (2009) (33)
- FibroTest and Fibroscan performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate. (2011) (33)
- NASH: a hidden and silent fibroser finally revealed? (2005) (32)
- Treatment of NASH with ursodeoxycholic acid: pro. (2012) (32)
- The association between adipocytokines and biomarkers for nonalcoholic fatty liver disease-induced liver injury: a study in the general population (2012) (32)
- RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease (2020) (31)
- Effects of interferon therapy in "non responder" patients with chronic hepatitis C. (1999) (31)
- Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. (2022) (30)
- Relationship Among Fatty Liver, Specific and Multiple‐Site Atherosclerosis, and 10‐Year Framingham Score (2019) (30)
- The impact of obesity and metabolic syndrome on chronic hepatitis B and drug-induced liver disease. (2014) (29)
- Non‐pharmacological interventions in non‐alcoholic fatty liver disease patients (2017) (29)
- Prognostic value of liver fibrosis and steatosis biomarkers in type‐2 diabetes and dyslipidaemia (2014) (28)
- Breakthroughs in therapies for NASH and remaining challenges. (2022) (27)
- Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C. (2014) (27)
- Applicability and variability of liver stiffness measurements according to probe position. (2009) (27)
- Cenicriviroc placebo for the treatment of non-alcoholic steatohepatitis with liver fibrosis: Results from the Year 1 primary analysis of the Phase 2b CENTAUR study (2016) (27)
- 1021 GLOBAL INVESTIGATION OF THERAPEUTIC DECISIONS IN HEPATOCELLULAR CARCINOMA (HCC) AND OF ITS TREATMENT WITH SORAFENIB (GIDEON): IMPACT OF LIVER DYSFUNCTION ON SORAFENIB TREATMENT IN EUROPE (2012) (26)
- Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis (2019) (26)
- 1207 TRIPLE THERAPY WITH DACLATASVIR (DCV; BMS-790052), PEGINTERFERON ALFA-2A AND RIBAVIRIN IN HCV-INFECTED PRIOR NULL AND PARTIAL RESPONDERS: 12-WEEK RESULTS OF PHASE 2B COMMAND-2 TRIAL (2012) (26)
- The times they are a-changin' (for NAFLD as well). (2020) (26)
- Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison (2016) (26)
- Ranking hepatologists: which Hirsch's h-index to prevent the "e-crise de foi-e"? (2011) (25)
- Current and Future Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH) (2017) (25)
- Nonalcoholic fatty liver disease increases the risk of hepatocellular carcinoma in patients with alcohol-associated cirrhosis awaiting liver transplants. (2015) (25)
- Prediction of oesophageal varices with platelet count/spleen diameter ratio or platelets alone. (2004) (25)
- EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. (2021) (25)
- Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease. (2021) (24)
- European ‘NAFLD Preparedness Index’ — Is Europe ready to meet the challenge of fatty liver disease? (2021) (24)
- Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. (2021) (24)
- Hepatic stellate cell hypertrophy is associated with metabolic liver fibrosis (2020) (23)
- Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis. (2021) (23)
- Long‐term prognostic value of the FibroTest in patients with non‐alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease (2018) (23)
- Binding of apolipoprotein A‐I and acetaldehyde‐modified apolipoprotein A‐I to liver extracellular matrix (1996) (23)
- Efficacy and safety of simtuzumab for the treatment of nonalcoholic steatohepatitis with bridging fibrosis or cirrhosis: results of two phase 2b, dose-ranging, randomized, placebo-controlled trials (2017) (22)
- SAT-357-Tropifexor, a farnesoid X receptor agonist for the treatment of non-alcoholic steatohepatitis: Interim results based on baseline body mass index from first two parts of Phase 2b study FLIGHT-FXR (2019) (22)
- Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. (2021) (22)
- Liver Stiffness by Transient Elastography to Detect Porto‐Sinusoidal Vascular Liver Disease With Portal Hypertension (2020) (22)
- Bone morphogenetic protein 8B promotes the progression of non-alcoholic steatohepatitis (2020) (21)
- Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients (2014) (21)
- Transcriptional Activation of Transforming Growth Factor β1 and Its Receptors by the Kruppel-like Factor Zf9/Core Promoter-binding Protein and Sp1 (1998) (21)
- Impact of interferon-alpha treatment on liver fibrosis in patients with chronic hepatitis B: an overview of published trials. (2009) (21)
- Unsuccessful rescue therapy with adefovir dipivoxil for lamivudine resistant HBV in a patient with liver failure (2003) (20)
- Is antiviral treatment (IFN alpha and/or ribavirin) justified in cirrhosis related to hepatitis C virus? Société Royale Belge de Gastro-entérologie. (1998) (20)
- Yet more evidence that MAFLD is more than name change. (2021) (20)
- Anti-tumor necrosis factor-alpha therapy in severe alcoholic hepatitis: are large randomized trials still possible? (2003) (19)
- Cenicriviroc treatment for adults with non-alcoholic steatohepatitis: Year 2 analysis of the Phase 2b CENTAUR study (2018) (19)
- 738 A one year randomized, placebo-controlled, double-blind trial of rosiglitazone in non-alcoholic steatohepatitis: Results of the flirt pilot trial (2006) (19)
- 1195 BMS-650032, AN NS3 INHIBITOR, IN COMBINATION WITH PEGINTERFERON ALPHA-2A AND RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION (2011) (19)
- Fecal Microbiota Transplant from Human to Mice Gives Insights into the Role of the Gut Microbiota in Non-Alcoholic Fatty Liver Disease (NAFLD) (2021) (19)
- FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase‐to‐platelet ratio index in patients with chronic hepatitis C (2007) (18)
- Touching some firm ground in the epidemiology of NASH. (2012) (18)
- Quantification of apolipoprotein A‐I and B messenger RNA in heavy drinkers according to liver disease (1996) (18)
- Is mipomersen ready for clinical implementation? A transatlantic dilemma (2013) (18)
- Real Time Identification of Drug-Induced Liver Injury (DILI) through Daily Screening of ALT Results: A Prospective Pilot Cohort Study (2012) (17)
- Performances of Elasto-FibroTest(®), a combination between FibroTest(®) and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C. (2012) (17)
- Continuous infusion of high‐dose omeprazole is more effective than standard‐dose omeprazole in patients with high‐risk peptic ulcer bleeding: a retrospective study (2007) (17)
- Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis (2021) (17)
- Worsening of steatosis and fibrosis progression (2003) (16)
- The elusiveness of “normal” ALT in fatty liver (2004) (16)
- SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients (2014) (16)
- FAS promoter polymorphisms correlate with activity grade in hepatitis C patients (2005) (16)
- Comparison of ADAPT, FIB4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR Screening Population. (2021) (16)
- Regenerate: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Multicenter Study of Obeticholic Acid Therapy for Nonalcoholic Steatohepatitis (2016) (16)
- Hepatic molecular effects of rosiglitazone in human non‐alcoholic steatohepatitis suggest long‐term pro‐inflammatory damage (2014) (16)
- HCV-GenoFibrotest: a combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C. (2011) (15)
- Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study. (2021) (15)
- 1096 ASUNAPREVIR (ASV; BMS-650032), AN NS3 PROTEASE INHIBITOR, IN COMBINATION WITH PEGINTERFERON AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION (2012) (15)
- Back to Byzance: Querelles byzantines over NASH and fibrosis. (2017) (15)
- Real-World Burden of Nonalcoholic Steatohepatitis. (2020) (15)
- Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers. (2020) (14)
- 729 Diagnostic value of biochemical markers (fibrotest) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) (2003) (14)
- Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference (2018) (14)
- Apolipoprotein A1 and hepatic fibrosis. (1995) (14)
- The diagnostic value of combining carbohydrate-deficient transferrin, fibrosis, and steatosis biomarkers for the prediction of excessive alcohol consumption (2009) (13)
- Dihydroceramides in Triglyceride-Enriched VLDL Are Associated with Nonalcoholic Fatty Liver Disease Severity in Type 2 Diabetes (2020) (13)
- Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice. (2020) (13)
- Serum fibrosis markers: death by validation or a leap of faith? (2010) (13)
- Diagnostic value of FibroTest with normal serum aminotransferases (2006) (13)
- Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis (2015) (13)
- Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?". (2014) (13)
- Liver biopsy: the best standard...when everything else fails. (2009) (13)
- Starting the battle to control non-alcoholic steatohepatitis (2015) (13)
- A comparison of the fibrotic potential of nonalcoholic fatty liver disease and chronic hepatitis C. (2010) (13)
- Pharmacological therapy for non‐alcoholic steatohepatitis: How efficient are thiazolidinediones? (2011) (12)
- 104 A CANDIDATE-GENE APPROACH TO VALIDATION OF GENETIC MODIFIER ASSOCIATIONS USING A LARGE COHORT WITH HISTOLOGICALLY CHARACTERISED NON-ALCOHOLIC FATTY LIVER DISEASE (2013) (12)
- Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery (2017) (12)
- Non-Alcoholic Fatty Liver Disease: Diagnosis and Investigation (2014) (12)
- Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study. (2015) (12)
- Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease (2020) (12)
- NAFLD: The evolving landscape. (2018) (12)
- Hirsch Index and Truth Survival in Clinical Research (2010) (12)
- Initial assessment and ongoing monitoring of lysosomal acid lipase deficiency in children and adults: Consensus recommendations from an international collaborative working group. (2019) (12)
- Changes in Fibrosis, but not the Nafld Activity Score (NAS), are Associated with Disease Progression in Patients with Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis (2017) (11)
- Performance of serum apolipoprotein-A1 as a sentinel of Covid-19 (2020) (11)
- Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study. (2015) (11)
- LCR1 and LCR2, two multi‐analyte blood tests to assess liver cancer risk in patients without or with cirrhosis (2018) (11)
- Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery (2022) (11)
- FibroTest is effective in patients with normal transaminases, when accuracy is standardized on fibrosis stage prevalence (2008) (11)
- The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis (2018) (11)
- Serum biochemical markers of liver fibrosis in human immunodeficiency virus (HIV) and hepatitis C virus (HCV)-coinfected patients (2002) (11)
- 1420 ASUNAPREVIR WITH PEGINTERFERON-ALFA AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE-1 OR -4 CHRONIC HEPATITIS C: SVR24 RESULTS FROM A RANDOMIZED PHASE 2B STUDY (AI447016) (2013) (10)
- Discussion on celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure. (2002) (10)
- Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors (2021) (10)
- Can nonalcoholic steatohepatitis be diagnosed without liver biopsy? (2009) (10)
- Predictive value of liver damage for severe early complications and survival after heart transplantation: A retrospective analysis. (2018) (10)
- Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations from the Multi-stakeholder Liver Forum. (2020) (10)
- Impact of steatosis and inflammation definitions on the performance of NASH tests (2017) (10)
- Impact of Sarcopenia on the Severity of the Liver Damage in Patients With Non-alcoholic Fatty Liver Disease (2022) (10)
- Anti-hepatitis C virus antibody detection in oral fluid: influence of human immunodeficiency virus co-infection. (2013) (10)
- Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis (2020) (9)
- When the journey from obesity to cirrhosis takes an early start. (2016) (9)
- ENTECAVIR AND TENOFOVIR COMBINATION THERAPY IN CHRONIC HEPATITIS B : RESCUE THERAPY IN PATIENTS WITH ADVANCED FIBROSIS AND MULTIPLE PREVIOUS TREATMENT FAILURES. RESULTS FROM AN INTERNATIONAL MULTICENTER COHORT STUDY (2009) (9)
- 86 Diagnostic value of two new biomarkers (steatotest and NASHtest) for the prediction of steatosis and non-alcoholic steato-hepatitis (NASH) (2006) (9)
- Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity (2015) (9)
- Prolonged therapy for hepatitis C with low-dose peginterferon. (2009) (9)
- Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease (2022) (9)
- Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance (2021) (9)
- Glitazones for human nonalcoholic steatohepatitis (2011) (9)
- Further delineation of fibrosis progression in NAFLD: evidence from a large cohort of patients with sequential biopsies (2017) (8)
- Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score (2022) (8)
- Chronic calcifying pancreatitis and systemic lupus erythematous. (2005) (8)
- 47 A MULTICENTRIC, DOUBLE-BLIND, RANDOMISED- CONTROLLED TRIAL (RCT) OF HIGH DOSE URSODEOXYCHOLIC ACID IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) (2009) (8)
- The EPoS staging system is a reproducible 7-tierfibrosis score for NAFLD adapted both to glass slides and digitized images (e-slides) (2018) (8)
- Performances of Elasto-FibroTest ® , a combination between FibroTest ® and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C (2012) (7)
- Real-life Perception and Practice Patterns of NAFLD/NASH in Romania: Results of a Survey Completed by 102 Board-certified Gastroenterologists. (2016) (7)
- Age and gender will survive to competing risks as fibrosis factors. (2005) (7)
- TM6SF2 rs58542926 influences hepatic fibrosis (2015) (7)
- 549 Hepatitis C in 2,410 patients 65 years or older. A severe and neglected curable disease? (2003) (7)
- OTU-14 Positive results from REGENERATE: a phase 3 international, randomized, placebo-controlled study evaluating obeticholic acid treatment for NASH (2019) (6)
- Performance of the PROC 3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease (2019) (6)
- [Hepatotoxicity of metastatic colorectal cancer chemotherapy: systematic review]. (2010) (6)
- [755] UTILITY OF A COMBINATION OF NON-INVASIVE BIOMARKERS (FIBROMAX) IN ASSESSING THE EFFICACY OF ROSIGLITAZONE IN A ONE YEAR RANDOMIZED, DOUBLE-BLIND TRIAL IN NON ALCOHOLIC STEATOHEPATITIS (2007) (6)
- 84 SAFETY, TOLERABILITY AND PRELIMINARY ACTIVITY OF GS-9450, A SELECTIVE CASPASE INHIBITOR, IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) (2010) (6)
- A new non-invasive diagnostic score to monitor change in disease activity and predict fibrosis evolution in patients with NASH (2017) (6)
- [792] IMPACT OF ADEFOVIR DIPIVOXIL ON LIVER FIBROSIS AND ACTIVITY ASSESSED WITH FIBROTEST-ACTITEST IN PATIENTS WITH CHRONIC HEPATITIS B INFECTION (2007) (5)
- Validation of NIS4 algorithm for detection of NASH at risk of cirrhosis in 467 NAFLD patients prospectively screened for inclusion in the RESOLVE-IT trial (2018) (5)
- Portal fibroblasts with mesenchymal stem cell features form a reservoir of proliferative myofibroblasts in liver fibrosis (2022) (5)
- Biomarkers as non‐invasive assessment of hepatic fibrosis in chronic hepatitis C (2004) (5)
- Hepatocellular Carcinoma in NAFLD (2007) (5)
- 938 Positive Results From REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH (2019) (5)
- Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes (2019) (5)
- 597 Diagnostic value of biochemical markers (fibrotest) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD) (2004) (5)
- Infections with Multiple Hepatotropic Viruses (2002) (5)
- 559 An overview of biochemical markers (fibrotest-actitest) diagnostic value in chronic liver diseases: A non-invasive alternative to liver biopsy (2003) (5)
- Impact of weight reduction on serum markers and liver histology including progression to cirrhosis in patients with nonalcoholic steatohepatitis (NASH) and bridging fibrosis (2017) (5)
- [766] NON INVASIVE TESTS OF LIVER FIBROSIS IN NAFLD (2007) (5)
- The painful reality of end-stage liver disease in NASH. (2018) (5)
- Reproducibility of non-invasive fibrosis biomarkers, FibroMeter and FibroTest, could be improved by respecting the analytical standardizations. (2008) (5)
- Progression of Fibrosis (2007) (4)
- 1075 Diagnostic value of biochemical markers (fibrotest) for the prediction of liver fibrosis in patients with chronic alcoholic liver disease (ALD) (2003) (4)
- Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and Cons. (2022) (4)
- 5 THE EMERGING IMPACT OF HEPATOCELLULAR CARCINOMA ARISING ON A BACKGROUND OF NAFLD (2012) (4)
- [240] APPLICABILITY OF NON-INVASIVE METHODS FOR THE DIAGNOSIS OF LIVER INJURY, LIVER STIFFNESS MEASURES (LSM) OR BIOMARKERS, AND FACTORS ASSOCIATED WITH NON-APPLICABILITY (2007) (4)
- [Nonalcoholic fatty liver disease: 30 years research changed NASH]. (2009) (4)
- UEG Week 2016 Poster Presentations (2016) (4)
- Impact of high serum glucose on liver fibrosis in chronic hepatitis C (CHC) (2001) (4)
- Obeticholic acid treatment in patients with non-alcoholic steatohepatitis: a secondary analysis of the REGENERATE study across fibrosis stages (2020) (4)
- Truth survival. Authors' reply (2002) (4)
- Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH) (2021) (4)
- Defi nition and management of radioactive iodine-refractory diff erentiated thyroid cancer (2014) (4)
- Final analysis of European patients from the Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib (GIDEON) study: Baseline characteristics and staging systems. (2014) (4)
- Management of nonalcoholic steatohepatitis: Pharmacotherapy (2012) (4)
- External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV (2021) (3)
- Hepatic fibrosis is associated with histological activity in nonalcoholic steatohepatitis: an analysis from a large database of screening biopsies in the CENTAUR trial (2017) (3)
- 21 10-YEARS PROGNOSTIC VALUE OF FIBROTEST AND STEATOTEST FOR LIVER-RELATED AND CARDIOVASCULAR DEATH IN PATIENTS WITH TYPE-2 DIABETES AND/OR HYPERLIPIDEMIA (2013) (3)
- 1034 REAL-WORLD MANAGEMENT OF HCC WITH SORAFENIB AND TACE IN EUROPE FROM GIDEON (GLOBAL INVESTIGATION OF THERAPEUTIC DECISIONS IN HCC AND OF ITS TREATMENT WITH SORAFENIB) (2012) (3)
- Arterial hypertension as an uninvited player in hepatic stiffness? (2016) (3)
- Quantitative genome-scale analysis of human liver reveals dysregulation of glycosphingolipid pathways in progressive nonalcoholic fatty liver disease (2021) (3)
- SAT-299-Assessment of NIS4 clinical utility for identification of patients with active NASH (NAS ≥ 4) and significant fibrosis (F ≥ 2) in patients at risk of NASH (2019) (3)
- Screening HIV patients at risk for NAFLD using MRI-PDFF and transient elastography: a European multicenter prospective study. (2022) (3)
- External validation of an algorithm combining multi‐analyte blood tests (FibroTest‐LCR1‐LCR2) to identify subjects at risk of hepatocellular carcinoma in patients with chronic liver disease (2019) (3)
- Blood Tests to Diagnose Fibrosis or Cirrhosis in Patients With Chronic Hepatitis C Virus Infection (2013) (3)
- Diagnosis and treatment of viral liver fibrosis. (2005) (3)
- P832 CLINICAL VALIDATION OF THE FLIP ALGORITHM AND SAF SCORE IN NON-ALCOHOLIC FATTY LIVER DISEASE (2014) (3)
- Letter: FibroTest for staging fibrosis in non‐alcoholic fatty liver disease (2013) (3)
- Benefit of Treatment With Sebelipase-Alfa in a 63-Year-Old Patient With Advanced Liver and Atherosclerotic Disease Due to Lysosomal Acid Lipase Deficiency (LAL-D) (2018) (3)
- Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH. (2022) (3)
- Targeting non-alcoholic fatty liver disease through 11-βHSD1 inhibition. (2014) (3)
- 357 - Cenicriviroc Treatment for Adults with Non-Alcoholic Steatohepatitis: Year 2 Analysis of the Phase 2B Centaur Study (2018) (3)
- 1020 SAFETY AND EFFICACY OF ENTECAVIR AND TENOFOVIR COMBINATION-THERAPY IN HEPATITIS B PATIENTS WITH PREVIOUS TREATMENT FAILURES. AN INTERNATIONAL MULTICENTER COHORT STUDY (2010) (3)
- FibroStic: a large confirmatory study for non-invasive biomarkers accuracy, if correctly interpreted. (2011) (3)
- [Adherence to pegylated combination therapy in patients with chronic hepatitis C. Importance of the hepatologist, general practitioner, and nurse]. (2008) (3)
- EDP-305, a non-bile acid farnesoid X receptor (FXR) agonist, showed statistically significant improvements in liver biochemistry and hepatic steatosis in the phase 2a argon-1 study (2020) (3)
- The Risk of Multiplying Diagnostic Combinations in the Absence of a Perfect Gold Standard For a Fibrosis Test (2011) (3)
- Real life study of bulevirtide in chronic hepatitis delta: preliminary results of the ANRS HD EP01 BuleDelta prospective cohort (2022) (2)
- Reply to "Establishing the independence and clinical importance of non-alcoholic fatty liver disease as a risk factor for cardiovascular disease". (2016) (2)
- Next-Generation Sequencing (NGS) of two independent cohorts identifies eleven circulating miRNAs for diagnosis of NASH and fibrosis (2017) (2)
- 1364 THE HOMA INDEX IS A USEFUL TOOL FOR RISK STRATIFICATION OF ADVANCED FIBROTIC DISEASE IN A LARGE COHORT OF EUROPEAN NAFLD PATIENTS (2013) (2)
- Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial (2023) (2)
- Pharmacological agents for nonalcoholic steatohepatitis (2013) (2)
- Obeticholic acid improves experimental non-invasive markers of non-alcoholic steatohepatitis and advanced fibrosis: a secondary analysis of the phase 3 regenerate study (2020) (2)
- A New, Non-Invasive Scale for Steatosis Developed Using Real-World Data From Russian Outpatients to Aid in the Diagnosis of Non-Alcoholic Fatty Liver Disease (2020) (2)
- 56 LONG-TERM EFFICACY OF ROSIGLITAZONE IN NONALCOHOLIC STEATOHEPATITIS (NASH): RESULTS OF THE EXTENSION PHASE OF THE FLIRT-2 TRIAL (2009) (2)
- 987 A COMPARISON BETWEEN THE HEPATORENAL ULTRASOUND INDEX AND STEATOTEST FOR THE NON-INVASIVE QUANTIFICATION OF LIVER STEATOSIS (2008) (2)
- FRI-355-Elafibranor, a drug candidate for first line NASH monotherapy and a universal backbone for drug combination treatment (2019) (2)
- Novel first-in-class, fatty acid synthase inhibitor, TVB-2640 vs. placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH: a phase 2 randomised controlled trial (FASCINATE-1) (2020) (2)
- T1014 Hepatitis C Infection (HCV) and Risk of Diabetes Mellitus: A Systematic Review and Meta-Analysis (2008) (2)
- Correction: An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load (2008) (2)
- Appropriate evidence‐based data overviews demonstrate the diagnostic and prognostic performances of FibroTest in patients with chronic hepatitis C (2009) (2)
- [556] PREVALENCE OF EACH FIBROSIS STAGE IS A MAJOR FACTOR OF VARIABILITY WHEN ASSESSING THE AREA UNDER THE ROC CURVES IN THE EVALUATION OF LIVER FIBROSIS MARKERS (2007) (2)
- Quantitative modeling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease (2022) (2)
- Impact of modest weight reduction on liver histology, portal pressure, and clinical events in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (2017) (2)
- A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures (2023) (2)
- Diagnostic value of fibrosis biochemical markers for the prediction of portal hypertension in chronic liver disease (2003) (2)
- Improving NASH with a little help from thyromimetics (2019) (2)
- Corrigendum to: "Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort"☆ (J Hepatol [2020] 505-515). (2021) (2)
- An international survey on patterns of practice in NAFLD and expectations for therapies—The POP‐NEXT project (2022) (2)
- Combination drug therapy allows synergistic therapeutic dose reduction in NASH: a case study of elafibranor (GFT505) and an FXR agonist combination in a model of severe NASH (2017) (2)
- 334 OBETICHOLIC ACID IMPROVES EXPERIMENTAL NON-INVASIVE MARKERS OF NON-ALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS; RESULTS OF A SECONDARY ANALYSIS FROM THE MONTH-18 INTERIM ANALYSIS OF THE REGENERATE STUDY (2020) (2)
- 873 PROGRESSION OF NAFLD IN HUMANS IS ASSOCIATED WITH THE ACTIVATION OF THE RENIN-ANGIOTENSIN SYSTEM (2011) (2)
- 403 CLINICALLY SIGNIFICANT VARIABILITY OF LIVER STIFFNESS MEASUREMENTS ALTERS SHORT-TERM FOLLOW-UP OF PATIENTS WITH CHRONIC LIVER DISEASES (2010) (2)
- Relationship between Baseline Hepatic Disease Severity and the Cardiometabolic and Anti-Inflammatory Effects of Elafibranor in Patients with Non-Alcoholic Steatohepatitis (2016) (2)
- Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. (2023) (2)
- The economic cost and health burden of non-alcoholic steatohepatitis (NASH) in the EU5 countries (2020) (1)
- Regenerate: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Multicenter Study of Obeticholic Acid Therapy for Nonalcoholic Steatohepatitis: 2502 (2016) (1)
- [What are the indications for treatment of acute hepatitis C?]. (2002) (1)
- THE INTERNATIONAL LIVER CONGRESS 2018 European Association for the Study of the Liver (EASL) (2018) (1)
- PLPNA3 Status in Nash is Associated with Increased Histological Severity at Baseline but Not with Response to Therapy in the Golden-505 Elafibranor Trial (2016) (1)
- Screening studies of transient elastography and FibroTest in the general population. (2017) (1)
- 1021 SCREENING FOR LIVER ADVANCED FIBROSIS USING NON-INVASIVE BIOMARKER FIBROTEST IN GENERAL POPULATION (2009) (1)
- Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19 (2022) (1)
- Prediction of fibrosis improvement in patients with advanced fibrosis due to NASH using a machine learning approach: Unravelling the placebo response (2018) (1)
- A217 NONINVASIVE ASSESSMENTS TO IDENTIFY PATIENTS WITH ADVANCED FIBROSIS DUE TO NASH: SCREENED POPULATION FROM THE REGENERATE TRIAL (2021) (1)
- Evaluation of PXL065 - Deuterium-Stabilized (R)-Pioglitazone in NASH Patients: a Phase 2 randomized placebo-controlled trial (DESTINY-1). (2023) (1)
- External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B (2022) (1)
- A New Method including the Quantification of Circulating Mirnas Allows the Efficient Identification of Nash Patients at Risk who should be Treated (2016) (1)
- Two new blood tests for identifying patients with chronic liver diseases, at high risk of primary liver cancer (2018) (1)
- PC.01.9 EVALUATION OF OBETICHOLIC ACID EFFICACY IN PATIENTS WITH NASH WHO WERE MONITORED USING NONINVASIVE TESTS: A POST HOC ANALYSIS OF THE REGENERATE TRIAL (2021) (1)
- A Post-Hoc Analysis ofthe Golden505 Trial Demonstrates Histological and Cardiometabolic Efficacy of Elafibranor-120 Mg in Patients with Moderate or Severe Nash That Are Eligible for Pharmacotherapy (2016) (1)
- 507 APRI and FIB-4 Index Scores Can Enrich for Subjects With Fibrotic Non-Alcoholic Steatohepatitis (NASH) in Clinical Trials - The CENTAUR Trial Data (2016) (1)
- Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study. (2023) (1)
- O26 NAFLD IS AN INDEPENDENT PREDICTOR OF EARLY CAROTID ATHEROSCLEROSIS: RESULTS FROM A LARGE TRANSVERSAL STUDY AND LONG-TERM FOLLOW-UP VALIDATION COHORT (2014) (1)
- 282 Diagnostic value of fibrosis biochemical markers (fibrotest) for the prediction of portal hypertension in chronic liver disease (2003) (1)
- [Nonalcoholic steatohepatitis]. (2005) (1)
- Correlation between the Hepatic Venous Pressure Gradient and Alpha-Smooth Muscle Actin (SMA) Expression in Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (2016) (1)
- From the Editor's Desk…. (2021) (1)
- Long term prognostic value of the FibroTest in patients with non-alcoholic-fatty-liver disease (NAFLD), compared to chronic hepatitis C (CHC), B (CHB), and alcoholic liver disease (ALD) (2018) (1)
- Tu1665 OBETICHOLIC ACID IMPROVES HEPATIC FIBROINFLAMMATION AS ASSESSED BY MULTIPARAMETRIC MRI: INTERIM RESULTS OF THE REGENERATE TRIAL (2020) (1)
- The combination of elafibranor and semaglutide drastically improves fibrosing steatohepatitis and distinctly modulates liver inflammatory signature (2020) (1)
- P213 Obeticholic acid improves hepatic fibroinflammation assessed by multiparametric MRI: interim results of the regenerate trial (2020) (1)
- [Hepatotoxicity of moxisylyte chlorhydrate: a new case]. (1991) (1)
- SAT-350-YH25724, a novel long-acting GLP-1/FGF21 dual agonist, exhibits marked anti-fibrotic effects in different experimental models of liver fibrosis (2019) (1)
- Rational Combination Therapy for NASH: Insights from Clinical Trials and Error. (2023) (1)
- 383 A COMPARISON OF FATTY LIVER INDEX WITH THREE NON-INVASIVE METHODS FOR THE DETECTION AND QUANTIFICATION OF LIVER STEATOSIS: REGULAR ULTRASOUND, HEPATORENAL ULTRASOUND INDEX AND STEATOTEST (2010) (1)
- Relationship between fatty liver, coronary calcium score, multiple-sites atherosclerosis and 10-years Framingham Score (2017) (1)
- Accuracy of Noninvasive Diagnostic Tests for the Detection of Significant and Advanced Fibrosis Stages in Nonalcoholic Fatty Liver Disease: A Systematic Literature Review of the US Studies (2022) (1)
- 744 TREATMENT OF MULTIRESISTANT HBV PATIENTS WITH ENTECAVIR PLUS TENOFOVIR. 2 YEARS SAFETY AND EFFICACY ANALYSIS. AN INTERNATIONAL MULTICENTER COHORT STUDY (2011) (1)
- 224 NON-INVASIVE PREDICTION OF UPPER GASTROINTESTINAL BLEEDING BY RUPTURE OF ESOPHAGEAL VARICES (ROV) USING LIVER AND SPLEEN STIFFNESS (AIXPLORER), LIVER STIFFNESS BY FIBROSCAN AND FIBROTEST (2013) (1)
- The necroptosis-inducing pseudokinase mixed lineage kinase domain-like regulates the adipogenic differentiation of pre-adipocytes (2022) (1)
- 279-LB: NIS4, a Novel Blood Test, Can Identify "At-Risk" NASH (NAS>4 and Fibrosis>2) in T2D Patients (2019) (1)
- Laparoscopic treatment without cholecystectomy for gallbladder perforation after liver biopsy. (1993) (1)
- The scaffold-dependent function of RIPK1 in experimental non-alcoholic steatohepatitis (2022) (1)
- T1013 A Multicentric, Double-Blind, Randomized Placebo-Controlled Trial of High Dose Ursodeoxycholic Acid in Patients with Non-Alcoholic Steatohepatitis (NASH) (2009) (1)
- Editorial: it is not a wide‐open field for incretins ‐ collateral benefits favour the use of metformin in advanced non‐alcoholic steatohepatitis (2019) (1)
- [Hepatocellular carcinoma and non alcoholic steatohepatitis: are we looking at the tip of the iceberg?]. (2003) (1)
- 72 MAPPING EXPRESSION QUANTITATIVE TRAITS LOCI (eQTL) FOR PNPLA3 GENE IDENTIFIES ADDITIONAL SNPS ASSOCIATED WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) INDEPENDENT OF rs738409 (2013) (1)
- A diagnostic proposal for sarcopenic obesity in adults based on body composition phenotypes. (2022) (1)
- 56th EASD Annual Meeting of the European Association for the Study of Diabetes (2020) (1)
- Europe’s largest meta-analysis on the prevalence of non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and advanced fibrosis (F3-F4) (2020) (1)
- RIPK3 dampens mitochondrial bioenergetics and lipid droplet dynamics in metabolic liver disease (2022) (1)
- 664 AN ACCURATE DEFINITION OF THE STATUS OF INACTIVE HBSAG CARRIER (IC) BY A COMBINATION OF BIOMARKERS AND VIRAL LOAD (VL) (2008) (1)
- Corrigendum to “Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C” [J Hepatol 36 (2002) 812–818] (2002) (1)
- A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis (2021) (1)
- Review article: The need for more efficient and patient‐oriented drug development pathways in NASH—setting the scene for platform trials (2023) (0)
- The conundrum of cryptogenic liver disease with advanced fibrosis: Poor clinical outcomes without treatment options (2018) (0)
- Obeticholic acid improves hepatic fibroinflammation as assessed by multiparametric magnetic resonance imaging: interim results of the regenerate trial (2020) (0)
- Machine learning algorithm improves detection of NASH (NAS-based) and at-risk NASH, a development and validation study. (2023) (0)
- What Are the Best Diagnostic Modalities for Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis and Associated Fibrosis? A Summary of AALSD Trend Conference in NASH (154/120) (2020) (0)
- 1038 CAN SERUM LEPTIN AND ADIPONECTIN PREDICT LIVER INJURY IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD)? A STUDY IN THE GENERAL POPULATION (2009) (0)
- From the Editor’s Desk… (2001) (0)
- 118 METABOLIC FATTY-LIVER DISEASE INCREASES THE RISK OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH ALCOHOLIC CIRRHOSIS LISTED FOR LIVER TRANSPLANTATION (2013) (0)
- PGI27 THE BURDEN OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN THE EU5 COUNTRIES (2019) (0)
- Appropriateness of inclusion criteria according to transaminases ALT in studies assessing performances of non-invasive tests in type-2 diabetes patients (T2D) (2018) (0)
- Prevalence, severity and patterns of clinicalpractice in outpatient visits for suspected NAFLD – the German CONSTANS STUDY (2018) (0)
- Semaglutide 2.4 mg once weekly improved liver and metabolic parameters, and was well tolerated, in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial (2022) (0)
- Serum levels of miR-34a to rule-out NAFLD in healthy subjects and identify NAFLD patients with active NASH (NAS>= 4) and significant liver fibrosis (F >= 2) (2020) (0)
- From the Editor's Desk... (2021) (0)
- From the Editor's Desk…. (2021) (0)
- KLF 6 : their potential role in the response to vascular injury signaling components by cooperative interaction between Sp 1 and β and transforming growth factor-endoglin Transcriptional activation of (2002) (0)
- Cost utility analysis for screening for fibrotic NASH in the type 2 population from European countries (2022) (0)
- Metabolism of human liver on a genome scale in non-alcoholic fatty liver disease (2020) (0)
- P327 PROFILING NEW BIOMARKERS FOR THE DIAGNOSIS OF DRUG INDUCED LIVER NECROSIS. A PILOT STUDY ASSESSING PERFORMANCE OF CLEAVED OR FULL-LENGTH CYTOKERATIN 18, AND MICRO-RNA-122 (2014) (0)
- From the Editor's Desk... (2023) (0)
- From the Editor's Desk… (2020) (0)
- Discordance between results of biomarkers of fibrosis shows that it is at least a "ménage à deux". (2009) (0)
- ANSWERING PIVOTAL QUESTIONS IN THE DIAGNOSIS AND TREATMENT OF PRIMARY BILIARY CIRRHOSIS AND NON-ALCOHOLIC STEATOHEPATITIS Symposium Report from the Intercept Pharmaceuticals, Inc. Supported Satellite Symposium, held at the International Liver Congress™ 2015, the 50 th Annual Meeting of the (2015) (0)
- [Can metabolic steatohepatitis be treated?]. (2007) (0)
- 1363 CHARACTERIZATION OF THE GUT MICROBIOTA BY QUANTITATIVE METAGENOMICS: A PROMISING TOOL FOR RISK STRATIFICATION IN NAFLD PATIENTS (2013) (0)
- Hepatic RIPK3 signalling differentially modulates lipid metabolism and inflammation in non-alcoholic fatty liver disease (2020) (0)
- From the Editor’s Desk… (2021) (0)
- NAFLD Phenotype in Patients With V-ATPase Proton Pump Assembly Defects (2018) (0)
- Accurate prediction of clinical disease progression in patients with advanced fibrosis due to NASH using a Bayesian machine learning approach (2018) (0)
- Clinicians’ perspectives on barriers and facilitators for the adoption of non-invasive liver tests: a mixed-method study (2022) (0)
- P0789 : Effectiveness, safety and cost per SVR in GT4 hepatitis C patients treated with sofosbuvir-based therapies in real clinical practice: A Franco-German experience (SOFEX-4) (2015) (0)
- P1067 : Associations between antidiabetic and statin therapy and liver histology in patients with type 2 diabetes and non-alcoholic fatty liver disease (2015) (0)
- 1156 IS TRUTH SURVIVAL IN HEPATOLOGY ASSOCIATED WITH HIRSCH INDEX (H) (2010) (0)
- Simple non-invasive fibrosis scores identify patients with non-alcoholic fatty liver disease who progress to advanced fibrosis/cirrhosis:evidence from a large cohort of patients with sequential liver biopsies (2017) (0)
- From the Editor's Desk... (2022) (0)
- 963 A COMPARISON OF THE FIBROGENIC POTENTIAL OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND CHRONIC HEPATITIS C (HCV) BY MICROMORPHOMETRY (2008) (0)
- 1876-P: Impact of Diabetes on Liver Disease Progression in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH) (2019) (0)
- From the Editor's Desk... (2022) (0)
- From the Editor's Desk... (2022) (0)
- NASH is emerging as a leading cause of hospitalisation for cirrhosis: results from a real-life, prospective, consecutive cohort (2020) (0)
- P1039 APPLICABILITY (APP) CRITERIA FOR REAL-TIME SHEAR WAVE ELASTOGRAPHY (RT-SWE) BY AIXPLORER COMPARED TO TRANSIENT ELASTOGRAPHY (TE) BY FIBROSCAN AND TO FIBROTEST (2014) (0)
- [Pre-C mutations of the HBV]. (2002) (0)
- Diagnostic de la non alcoholic fatty liver disease : chez qui et comment ? (2017) (0)
- Reply: (2011) (0)
- Introducing the Expert Opinion series. (2020) (0)
- From the Editor's Desk... (2022) (0)
- From the Editor's Desk... (2021) (0)
- Signature of circulating hepatic proteins detects fibrosing-steatohepatitis in progressive non-alcoholic fatty liver disease (2022) (0)
- 1022 OVERESTIMATION OF “PURE” NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AS A CAUSE OF LIVER FIBROSIS (AF) USING ALCOHOL CONSUMPTION ESTIMATED BY SELF DECLARATION (SD) (2009) (0)
- From the Editor's Desk…. (2020) (0)
- P957 FINAL ANALYSIS OF AETIOLOGY/COMORBIDITIES IN EUROPEAN PATIENTS FROM THE GIDEON (GLOBAL INVESTIGATION OF THERAPEUTIC DECISIONS IN HEPATOCELLULAR CARCINOMA AND OF ITS TREATMENT WITH SORAFENIB) STUDY (2014) (0)
- 1316 METABOLIC COMORBIDITIES IN A LARGE FRENCH REAL-LIFE COHORT OF PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (2012) (0)
- T06.01.19 THE ECONOMIC COST AND HEALTH BURDEN OF NON-ALCOHOLIC STEATOHEPATITIS IN THE EU5 COUNTRIES (2020) (0)
- 1333 HCV-GENOFIBROTEST: A COMBINATION OF VIRAL, LIVER AND GENOMIC (IL28B, ITPA, UGT1A1) BIOMARKERS FOR PREDICTING TREATMENT RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS C (2011) (0)
- Hepatitis C infection and proteinuria. (2005) (0)
- Contents (2020) (0)
- CLINICAL — LIVER Ela fi branor, an Agonist of the Peroxisome Proliferator L Activated Receptor L a and L d , Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening (0)
- Treatment Targets and Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH): A Summary of AALSD Trend Conference in NASH (2020) (0)
- Long-term outcome improvement in patients with chronic hepatitis D treated with interferon α (2004) (0)
- From the Editor's Desk... (2020) (0)
- T06.01.12 OBETICHOLIC ACID (OCA) IMPROVES NON-INVASIVE MARKERS OF FIBROSIS IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH): A SECONDARY ANALYSIS OF THE PHASE 3 REGENERATE STUDY (2020) (0)
- Influence of Liver and Renal Impairments on Early Mortality in Heart Transplant Patients (2013) (0)
- Reply to Pattou et al. (2022) (0)
- Obeticholic acid (OCA) improves non-invasive markers of fibrosis in patients with non-alcoholic steatohepatitis (NASH): a secondary analysis of the phase 3 Regenerate study (2020) (0)
- 345 DIAGNOSTIC VALUE OF LIVER INJURY BIOMARKERS, FIBROTEST (FT), STEATOTEST (ST), NASHTEST (NT) IN PATIENTS WITHOUT ADVANCED DISEASE UNDERGOING BARIATRIC SURGERY (2010) (0)
- [Hepatitis B virus and hepatocellular carcinoma: the track of chromosome X]. (1993) (0)
- Newsletter No. 1 / 2008 (2008) (0)
- PS-191-External validation of an algorithm combining multi-analyte blood tests (FibroTest-LCR1-LCR2) for identifying subjects at risk of hepatocellular carcinoma among patients with chronic liver disease (2019) (0)
- NAFLD and NASH Biomarker Qualification in the LITMUS consortium - Lessons learned. (2022) (0)
- Corrigendum to: "Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆" [J Hepatol (2020) 505-515]. (2023) (0)
- Macrophage scavenger receptor 1 mediates lipid-induced inflammation in human obesity-related non-alcoholic fatty liver disease (2020) (0)
- AF.81 NONINVASIVE ASSESSMENTS TO IDENTIFY PATIENTS WITH ADVANCED FIBROSIS DUE TO NASH: SCREENED POPULATION FROM THE REGENERATE TRIAL (2021) (0)
- Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B (2003) (0)
- Contents (2020) (0)
- Liver disease progression and clinical outcomes in hepatic outcomes and survival fatty liver registry (HOTSURFR) study (2020) (0)
- From the Editor's Desk…. (2020) (0)
- Mo1448 OBETICHOLIC ACID IMPROVES TRANSAMINASES IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS: RESULTS FROM THE 18-MONTH INTERIM ANALYSIS OF THE REGENERATE STUDY (2020) (0)
- 949 Low HBV replication and liver fibrosis: the impact of race in a study of 552 chronic hepatitis B patients (2003) (0)
- Clinical endpoints are necessary in the interim analysis of REGENERATE – Authors' reply (2020) (0)
- From the Editor’s Desk… (2020) (0)
- From the Editor's Desk (1957) (0)
- From the Editor's Desk... (2021) (0)
- From the Editor's Desk... (2021) (0)
- [723] LIVER MITOCHONDRIAL FUNCTION AND BIOGENESIS IN PATIENTS WITH NAFLD: HEPATIC EXPRESSION OF PGC1-ALPHA, COX2 AND COX4 (2007) (0)
- Obeticholic acid demonstrates sustained improvements at month 24 in transaminases and non-invasive markers of fibrosis: Results of a post hoc analysis from the interim analysis of the REGENERATE study (2020) (0)
- 414 IMPACT OF SHEAR-WAVES CHARACTERISTICS ON THE MEDIAN LIVER STIFFNESS MEASURE (LSM) ASSESSED BY FIBROSCAN: EVALUATION WITH LIVER BIOPSY (LB) OF RISK OF FALSE NEGATIVE RESULTS (2010) (0)
- O26 Obeticholic acid improves experimental noninvasive markers of nonalcoholic steatohepatitis and advanced fibrosis: results from regenerate (2021) (0)
- P1002 : The histological severity of NAFLD determines the cardiovascular risk and insulin resistance in metabolically healthy and unhealthy overweight individuals (2015) (0)
- Reply (2022) (0)
- Prognostic value of 2D-shear wave elastography for staging cirrhosis in chronic liver diseases in two severity classes according to liver-related complications (2018) (0)
- Pharmacological Options for NASH (2020) (0)
- From the Editor's Desk... (2022) (0)
- From the Editor's desk…. (2021) (0)
- Adipose tissue insulin resistance and inflammation, but not reduced hepatic fat oxidation, are associated to active NASH and severe fibrosis (2020) (0)
- 326 OBESITY-SPECIFIC HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS: RESULTS FROM THE REGENERATE STUDY (2020) (0)
- A219 AMINOTRANSFERASE IMPROVEMENTS IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS ARE ASSOCIATED WITH FIBROSIS REGRESSION IN THE REGENERATE STUDY (2022) (0)
- P1024 PRESENCE OF HEPATIC STEATOSIS AS PER NON-INVASIVE BIOMARKERS OVERESTIMATES FIBROSIS STAGES BASED ON LIVER STIFFNESS MEASUREMENT (LSM) BY TRANSIENT ELASTOGRAPHY IN TYPE-2 DIABETIC (T2D) PATIENTS (2014) (0)
- Long-term outcome improvement in patients with chronic hepatitis D treated with interferon alpha. (2004) (0)
- 1356 NAFLD IS SIGNIFICANTLY INCREASED IN PATIENTS AT HIGH RISK FOR CARDIOVASCULAR EVENTS AND IS CORRELATED WITH EARLY PREDICTORS OF ATHEROSCLEROSIS AND THE FRAMINGHAM SCORE (2013) (0)
- 1355 HISTOLOGICAL SEVERITY INDEPENDENTLY PREDICTS EARLY ATHEROSCLEROTIC LESIONS AND 10 YEAR CARDIOVASCULAR RISK IN NAFLD PATIENTS (2013) (0)
- 440 Low HBV replication and liver fibrosis: The impact of race in a study of 552 chronic hepatitis B patients (2004) (0)
- OC-07A machine learning approach for the classification of NASH vs NAFL in diabetic and non-diabetic subjects reveals a strong association between liver inflammation and adipose tissue dysfunction (2021) (0)
- Bone morphogenetic protein 8B promotes the progression of non-alcoholic steatohepatitis (2020) (0)
- Obeticholic acid (OCA) improves experimental non-invasive markers of NASH and advanced fibrosis: results of a secondary analysis from the month-18 interim analysis of the REGENERATE study (2020) (0)
- High-throughput RNA sequencing unravels pathways associated with the progression of non-alcoholic liver disease (2017) (0)
- Future Treatment Options and Regimens for Nonalcoholic Fatty Liver Disease. (2023) (0)
- From the Editor’s Desk… (2001) (0)
- From the Editor's Desk…. (2021) (0)
- Higher daily Aramchol dose results in higher effect size in fibrosis improvement in the ARMOR study open label part (2022) (0)
- 487 LONG TERM SURVIVAL OF LIVER FIBROSIS AFTER VIROLOGICAL CURE (SVR) IN HIV–HCV COINFECTED PATIENTS: A WORRISOME LATENT DISEASE? (2013) (0)
- From the Editor's Desk…. (2020) (0)
- Contents (2020) (0)
- How to best diagnose NAFLD/NASH? (2016) (0)
- Serum Bile Acid Profiles are Associated with Histological Severity in Patients with Non-Alcoholic Fatty Liver Disease (2016) (0)
- PGI49 - HUMANISTIC BURDEN OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) – IN THE FIRST REAL-WORLD CROSS-SECTIONAL STUDY, SYMPTOMATIC NASH PATIENTS REPORT WORSE QUALITY OF LIFE (2018) (0)
- From the Editor's Desk... (2022) (0)
- Metabolomics approaches to identify biomarkers of non-alcoholic fatty liver disease (2020) (0)
- 1359 ASSOCIATION BETWEEN LIVER FIBROSIS AND DECREASED APOLIPOPROTEIN-A1 IN A 7-YEARS PROSPECTIVE STUDY. COULD IT EXPLAIN CARDIOVASCULAR-RELATED RISK WITH FIBROSIS PROGRESSION IN TYPE-2 DIABETIC PATIENTS? (2013) (0)
- Whole exome sequencing identifies rare nonsense mutations enriched among patients with advanced fibrosis due to nonalcoholic steatohepatitis (2018) (0)
- From the Editor's Desk…. (2020) (0)
- From the Editor's Desk... (2020) (0)
- 855 DIAGNOSTIC VALUE OF BIOMARKERS (FIBROTEST, ACHTEST, STEATOTEST AND NASHTEST) FOR THE PREDICTION OF LIVER INJURY IN 494 PATIENTS WITH SEVERE OBESITY (2011) (0)
- From the Editor's Desk... (2022) (0)
- P-0073 GIDEON (Global Investigation of Therapeutic Decisions in HCC and of its Treatment eith Sorafenib): European Interim Safety and Dosing Subanalysis (2012) (0)
- Hepatic and Extrahepatic Malignancies in NAFLD (2016) (0)
- From the Editor's Desk... (2023) (0)
- Reply to Jindal et al. (2022) (0)
- From the Editor's Desk... (2020) (0)
- PGI52 - DECREASED WORK PRODUCTIVITY AND INCREASED HEALTHCARE RESOURCE UTILISATION (HRU) AMONG PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) – RESULTS FROM A REAL WORLD EVIDENCE STUDY (2018) (0)
- [Palliative endoscopic treatment of malignant stenoses of the esophagus and cardia]. (1993) (0)
- Contents (2020) (0)
- Clinicians’ Perspectives on Barriers and Facilitators for the Adoption of Non-Invasive Liver Tests for NAFLD: A Mixed-Method Study (2022) (0)
- GENFIT : NEW PROOF OF EFFICACY OF GFT 505 IN NASH AND POSITIVE (2015) (0)
- [Non-alcoholic steatosis: limits of current knowledge and lessons for hepatologists]. (2003) (0)
- A proposal from the Liver Forum for the management of comorbidities in nonalcoholic steatohepatitis therapeutic trials. (2023) (0)
- 582 A prospective follow-up of discordances between biochemical markers and biopsy in patients with chronic hepatis C (CHC) (2003) (0)
- Designing an exploratory phase 2b platform trial in NASH with correlated, co-primary binary endpoints (2022) (0)
- The Cost of Diagnosing and Managing Non-alcoholic Steatohepatitis in Europe and the United States. (2022) (0)
- P862 LONGITUDINAL VALIDATION OF BIOMARKERS OF FIBROMAX PANEL, AS SURROGATES FOR DYNAMIC HISTOLOGICAL CHANGES ON LIVER BIOPSY (LB) IN NAFLD PATIENTS (2014) (0)
- High-throughput sequencing identified MIR-193a as a potential biomarker of non-alcoholic fatty liver disease activity (2020) (0)
- From the Editor's Desk... (2021) (0)
- A novel simple and reliable 2D-shear wave elastography (SWE) and ultrasound-guided coefficient attenuation parameter (SCAP) technique for patients with chronic liver disease (2022) (0)
- PWE-120 High rate of false positives for advanced fibrosis when simple non-invasive fibrosis tests are used in older patients (≥ 65 years) with nafld (2015) (0)
- Medical management of sporadic and hereditary gastrinoma: An update approach and its limits (1992) (0)
- 707 screening for advanced fibrosis using non-invasive biomarkers (Fibrotest Fibrosure) in diabetic patients (2006) (0)
- From the Editor's Desk… (2020) (0)
- The goal of therapy is to prevent complications and death from chronic viral hepatitis [2,4]. Because of the slow evolution of chronic hepatitis over sev- (2010) (0)
- 345 A NEW METHODOLOGY FOR ASSESSING PROGRESSION OF LIVER FIBROSIS IN LARGE POPULATIONS USING VALIDATED BIOMARKER FIBROTEST® INSTEAD OF BIOPSY (2011) (0)
- 1005 DOES LIVER IMPAIRMENT CORRELATE WITH EARLY MORTALITY IN HEART TRANSPLANT PATIENTS (2013) (0)
- Genome-Wide Association Study of Clinically Significant Portal Hypertension in Patients with Nonalcoholic Steatohepatitis and Advanced Fibrosis (2016) (0)
- A transcriptomic signature predicting fibrosis progression in a large European cohort of patients with histologically characterised NAFLD (2020) (0)
- 1155 INTERPRETABILITY AND REFERENCE VALUES OF LIVER INJURY BIOMARKERS FIBROTEST AND ACTITEST (FT-AT). A GLOBAL ANALYSIS OF 354,143 CONSECUTIVE ASSESSMENTS (2010) (0)
- Timing Is Everything: Improving NASH Histology in Clinical Trials Should Not Be Rushed (2020) (0)
- Hepatic stellate cell hypertrophy is associated with metabolic liver fibrosis (2020) (0)
- The journey of a patient with biopsy-proven non-alcoholic steatohepatitis (NASH) – results from a real-world study (2019) (0)
- 1064 FIBROTEST HAS NO GRAY ZONE FOR THE DIAGNOSIS OF FIBROSIS STAGES RELATIVE TO BIOPSY: THE GRAY ANATOMY OF 27869 VIRTUAL BIOPSIES AND 6500 PATIENTS (2012) (0)
- Liver Fibrosis Evaluation Using Real-Time Shear Wave Elastography: Applicability, Association with Activity and Steatosis, and Diagnostic Performance. Direct Comparisons with Transient Rlastography Using Biomarkers as References (2016) (0)
- Impact of NASH, gender, fasting glucose and body mass index on the liver fibrosis transition rate (FTR) in metabolic liver disease (MLD) (2017) (0)
- From the Editor's Desk…. (2020) (0)
- PNPLA3 Variants Confer an Increased Risk of Advanced Fibrosis Due to Non-Alcoholic Steatohepatitis (2016) (0)
- Serum bile acids are markedly elevated in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH) (2018) (0)
- Clinical Trial Landscape in NASH. (2023) (0)
- From the Editor's Desk... (2022) (0)
- [Mutations of the p53 gene in hepatocellular carcinomas]. (1992) (0)
- PGI10 MODELLING THE IMPACT OF TREATMENT WITH ENTECAVIR ON HEALTH CARE COSTS OF CHRONIC HEPATITIS B IN FRANCE (2010) (0)
- 1317 PERFORMANCE AND LIMITATIONS OF STEATOSIS MARKERS IN PATIENTS WITH NAFLD (2012) (0)
- Spectrum of NAFLD Severity in a Large Population using Software-Combined Tests of Steatosis, Necroinflammatory Activity, and Fibrosis (Fibromax) in Comparison with Patients with Chronic Hepatitis C (2016) (0)
- PS-058-The socio-economic burden of NASH in Europe and the United States: The gain study (2019) (0)
- 709 A multicentric prospective assessement of non-alcoholic fatty liver disease in french patients with chronic unexplained hypertransaminasemia (2006) (0)
- PDB74 USING FRENCH ADMINISTRATIVE DATABASE TO ASSESS PATIENTS WITH ADVANCED NON-ALCOHOLIC STEATOHEPATITIS (NASH) (2019) (0)
- 1334 DYSREGULATION OF HOST INNATE IMMUNITY IN HCV GENOTYPE 1 INFECTED IL28B CT/TT HAPLOTYPE PATIENTS WITH DEPRESSED VIRAL KINETICS AND THERAPEUTIC RESPONSE (2011) (0)
- Multimodality assessment of hepatic fibrosis: ranked paired reading and artificial intelligence identifies fibrosis improvement with aramchol missed by conventional staging (2022) (0)
- 418 GOLD-VALIDATION OF LIVER FIBROSIS ESTIMATES, FIBROTEST (FT) AND LIVER STIFFNESS MEASUREMENT (LSM), USING SURGICAL SAMPLES AND VIRTUAL BIOPSIES (2010) (0)
- Obesity-specific health-related quality of life in patients with non-alcoholic steatohepatitis: results from the regenerate study (2020) (0)
- The endoplasmic reticulum stress sensor IRE1 regulates collagen secretion through the enforcement of the proteostasis factor P4HB/PDIA1 contributing to liver damage and fibrosis (2023) (0)
- From the Editor's Desk... (2023) (0)
- HMG-COA REDUCTASE INHIBITORS (STATINS) AND METFORMIN ARE ASSOCIATED WITH PRESERVATION OF HEPATIC FUNCTION AND LESS PORTAL-SYSTEMIC SHUNTING IN ADVANCED CHRONIC LIVER DISEASE (2021) (0)
- Health-care burden of NAFLD in European hospital-based outpatient hepatology clinics: real-world prospective data from the CONSTANS study (2020) (0)
- Obeticholic Acid Efficacy in Patients With NASH Monitored Using Noninvasive Tests: Post Hoc Analysis of REGENERATE Trial (2021) (0)
- The risks of changing the rules for previously validated biomarkers and using the same patients several times. Response letter to Calès et al. Gastroenterol Clin Biol 2008;32:1050-60: "Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests". (2009) (0)
- From the Editor’s Desk… (2022) (0)
- Reliability of histologic disease activity measures in non-alcoholic fatty liver disease (NAFLD) and development of an expanded NAFLD activity score (2022) (0)
- 278-LB: Type 2 Diabetes (T2D) as a Risk Factor for NASH and Significant Liver Fibrosis (F>2) in an International Cohort of 2,363 Patients with Metabolic Steatosis (2019) (0)
- From the Editor's Desk... (2023) (0)
- 346 THE HAZARDS OF TRANSAMINASE ALT VALUE AS A MARKER OF LIVER FIBROSIS PROGRESSION: A GLOBAL ASSESSMENT IN PATIENTS USING VALIDATED BIOMARKER FIBROTEST® (2011) (0)
- From the Editor's Desk…. (2022) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Vlad Ratziu?
Vlad Ratziu is affiliated with the following schools:
